Blood:T细胞缺陷是携带ARPC1B突变的联合型免疫缺陷患者的致病因素

2018-09-26 MedSci MedSci原创

中心点:ARPC1B缺陷可改变T细胞增殖、细胞骨架、细胞迁移和免疫突触组装。功能性缺陷在自然逆转和体外转导的T细胞中得到纠正。摘要:ARPC1B是组装和维护ARP2/3复合物的关键因子,而ARP2/3复合物参与肌动蛋白从现有的丝状体分支出来。近期在6位联合型免疫缺陷患者的生殖细胞中发现ARPC1B等位基因突变,其中性粒细胞和血小板均被研究过,但T淋巴细胞尚未被研究过。研究人员推测ARPC1B缺陷可

中心点:

ARPC1B缺陷可改变T细胞增殖、细胞骨架、细胞迁移和免疫突触组装。

功能性缺陷在自然逆转和体外转导的T细胞中得到纠正。

摘要:

ARPC1B是组装和维护ARP2/3复合物的关键因子,而ARP2/3复合物参与肌动蛋白从现有的丝状体分支出来。近期在6位联合型免疫缺陷患者的生殖细胞中发现ARPC1B等位基因突变,其中性粒细胞和血小板均被研究过,但T淋巴细胞尚未被研究过。研究人员推测ARPC1B缺陷可能也会导致T细胞细胞骨架和功能障碍。

研究人员在6个表现为严重感染、自身免疫混乱和血小板减少的不相关的早发型患者中检测到ARPC1B等位基因突变。免疫学特征包括T淋巴细胞减少症、幼稚T细胞数量少和IgE过高。通过流式细胞术和共聚焦显微镜观察发现ARPC1B蛋白结构改变导致表达量减少或缺失。该分子缺陷与患者来源的T细胞不能在TCR的刺激下扩展富含肌动蛋白的板状伪足和不能组装成免疫突触相关。

此外,ARPC1B缺陷型T细胞还表现出TCR介导的增殖和SDF1-α-导向的迁徙障碍。在体外,采用慢病毒载体向患者T细胞转染ARPC1B基因,可恢复ARPC1B的表达和T细胞增殖。

两位患者体细胞逆转恢复了其部分淋巴细胞的ARPC1B表达。一例逆转的患者的ARPC1B表达水平正常的CD8+记忆T细胞的迁移能力提高。遗传ARPC1B缺陷可改变T细胞的细胞骨架动力和功能,导致临床联合型免疫缺陷。

原始出处:

Immacolata Brigida, et al.T cell defects in patients with ARPC1B germline mutations account for their combined immunodeficiency. Blood  2018  :blood-2018-07-863431;  doi: https://doi.org/10.1182/blood-2018-07-863431

本文系梅斯医学(MedSci)原创编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1946055, encodeId=a03b194605543, content=<a href='/topic/show?id=bef9864e4e4' target=_blank style='color:#2F92EE;'>#致病因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86474, encryptionId=bef9864e4e4, topicName=致病因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b1f500, createdName=zengjiayao, createdTime=Sat Aug 10 01:07:00 CST 2019, time=2019-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488983, encodeId=41a0148898358, content=<a href='/topic/show?id=7df32913871' target=_blank style='color:#2F92EE;'>#免疫缺陷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29138, encryptionId=7df32913871, topicName=免疫缺陷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631b8488299, createdName=rebeccajiejie, createdTime=Fri Sep 28 11:07:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346814, encodeId=760b34681410, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Sep 26 21:10:02 CST 2018, time=2018-09-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1946055, encodeId=a03b194605543, content=<a href='/topic/show?id=bef9864e4e4' target=_blank style='color:#2F92EE;'>#致病因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86474, encryptionId=bef9864e4e4, topicName=致病因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b1f500, createdName=zengjiayao, createdTime=Sat Aug 10 01:07:00 CST 2019, time=2019-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488983, encodeId=41a0148898358, content=<a href='/topic/show?id=7df32913871' target=_blank style='color:#2F92EE;'>#免疫缺陷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29138, encryptionId=7df32913871, topicName=免疫缺陷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631b8488299, createdName=rebeccajiejie, createdTime=Fri Sep 28 11:07:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346814, encodeId=760b34681410, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Sep 26 21:10:02 CST 2018, time=2018-09-26, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1946055, encodeId=a03b194605543, content=<a href='/topic/show?id=bef9864e4e4' target=_blank style='color:#2F92EE;'>#致病因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86474, encryptionId=bef9864e4e4, topicName=致病因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b1f500, createdName=zengjiayao, createdTime=Sat Aug 10 01:07:00 CST 2019, time=2019-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488983, encodeId=41a0148898358, content=<a href='/topic/show?id=7df32913871' target=_blank style='color:#2F92EE;'>#免疫缺陷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29138, encryptionId=7df32913871, topicName=免疫缺陷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631b8488299, createdName=rebeccajiejie, createdTime=Fri Sep 28 11:07:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346814, encodeId=760b34681410, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Sep 26 21:10:02 CST 2018, time=2018-09-26, status=1, ipAttribution=)]
    2018-09-26 医者仁心5538

    学习了

    0